Dietary Modification of Lower Urinary Tract Symptoms with Fermented Whey Product

DOI: 10.4236/oju.2013.32022   PDF   HTML     3,591 Downloads   5,586 Views   Citations

Abstract

After the age of 50, the prostate begins to increase in size. This is known as benign prostatic hypertrophy (BPH). Compression of urethra by enlarged prostate causes dribbling reduced force of the urinary stream, pain and occasional bleeding or infection. This causes difficulty in urinating and requires many men to get up several times during the night to urinate. The aim of our study was to evaluate an influence of new fermented whey based product (FWP) to several biochemical parameters and lower urinary tract symptoms (LUTS). Patients from the outpatient department of Andrology Center were randomized. This study involved the patients with minor to moderate LUTS, International Prostate Symptoms Score (IPSS) range 3 - 19 but not prostatitis (NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) < 4 and 2-glass test negative for prostate inflammation and infection). Consumption of the FWP decreased the IPSS score in patients with moderate LUTS/BPH (p < 0.001) whereas irritative and obstructive symptoms changed in parallel. There was a correlation between LUTS symptoms change and level of inflammation- and oxidative stress-related indices (blood high-sensitive C-reactive protein, hsCRP; glycated haemoglobin, HbA1c; oxidized low density lipoprotein, oxLDL; interleukine-10, IL-10 and 8-isoprostanes in the urine). Statistically significant changes in mentioned parameters occurred only in study group. Compression of urethra by enlarged prostate explains LUTS in BPH patients. Elevated oxidative stress (OxS) intensifies peroxidation of cell membrane phospholipids. This generates 8-isoprostanes (8-EPI), the prostaglandin-like compounds that can exaggerate LUTS. 8-isoprostanes may cause constriction of bladder and urethra in nanomolar concentrations. Consuming the whey-based product fermented by special lactobacilli strains may improve LUTS as well as OxS and diminish LUTS-related inflammatory response.

Share and Cite:

T. Kullisaar, S. Türk, M. Punab, A. Veskioja, E. Songisepp, K. Zilmer and M. Zilmer, "Dietary Modification of Lower Urinary Tract Symptoms with Fermented Whey Product," Open Journal of Urology, Vol. 3 No. 2, 2013, pp. 114-120. doi: 10.4236/oju.2013.32022.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] J. T. Wei, E. Calhoun and S. J. Jacobsen, “Urologic Diseases in America Project: Benign Prostatic Hyperplasia,” The Journal of Urology, Vol. 173, No. 4, 2005, pp. 1256-1261. doi:10.1097/01.ju. 0000155709.37840.fe
[2] J. K. Parsons, J. Bergstrom, J. Silberstein and E. BarrettConnor, “Prevalence and Characteristics of Lower Urinary Tract Symptoms in Men Aged > or = 80 Years,” Urology, Vol. 72, No. 2, 2008, pp. 318-321. doi:10.1016/j.urology.2008.03.057
[3] J. K. Parsons, “Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors,” Current Bladder Dysfunction Reports, Vol. 5, No. 4, 2010, pp. 212-218. doi:10.1007/s11884-010-0067-2
[4] G. Williams, “Aromatase Up-Regulation, Insulin and Raised Intracellular Oestrogens in Men, Induce Adiposity, Metabolic Syndrome and Prostate Disease, via Aberrant ER-α and GPER Signaling,” Molecular and Cellular Endocrinology, Vol. 351, No. 2, 2012, pp. 269-278. doi:10.1016/j. mce.2011.12.017
[5] S. Matsumoto, T. Hanai, T. Matsui, M. Oka, M. Tanaka and H. Uemura, “Eviprostat Suppresses Urinary Oxidative Stress in a Rabbit Model of Partial Bladder Outlet Obstruction and in Patients with Benign Prostatic Hyperplasia,” Phytotherapy Research, Vol. 24, No. 2, 2010, pp. 301-303.
[6] T. Tarcan, M. B. Siroky, R. J. Krane and K. M. Azadzoi, “Isoprostane 8-epi PGF2alpha, a Product of Oxidative Stress, Is Synthesized in the Bladder and Causes Detrusor Smooth Muscle Contraction,” Neurourology and Urodynamics, Vol. 19, No. 1, 2000, pp. 43-51. doi:10.1002/(SICI)1520-6777(2000)19:1<43::AID-NAU6>3.0.CO;2-C
[7] T. Kullisaar, M. Zilmer, E. Tammsaar, A. Veskioja, E. Songisepp, K. Zilmer, L. Bobrovski, K. Ehrlich, M. R?tsep, M. Punab, M. Vasar and M. Mikelsaar, “Isolated Strains of Microorganisms MCC1 DSM23881 and MCC2 DSM23882 and the Use Thereof,” Applicant Bio-Competence Centre of Healthy Dairy Products.
[8] E. Pihl, K. Zilmer, T. Kullisaar, C. Kairane, A. Pulges and M. Zilmer, “High-Sensitive C-Reactive Protein Level and Oxidative Stress-Related Status in Former Athletes in Relation of Traditional Cardiovascular Risk Factors,” Atherosclerosis, Vol. 171, No. 2, 2003, pp. 321-326. doi:10.1016/j.athe rosclerosis.2003.08.015
[9] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), “Scientific Opinion on the Substantiation of Health Claims Related to Polyphenols in Olive and Protection of LDL Particles from Oxidative Damage,” EFSA Journal, Vol. 9, No. 4, 2011, pp. 2033-2058.
[10] K. D. Kent, W. J. Harper and J. A. Bomser, “Effect of Whey Protein Isolate on Intracellular Glutathione and Oxidant-Induced Cell Death in Human Prostate Epithelial Cells,” Toxicology in Vitro, No. 17, 2003, pp. 27-33.
[11] S. Rahbar, “The Discovery of Glycated Hemoglobin: A Major Event in the Study of Nonenzymatic Chemistry in Biological Systems,” Annals of the New York Academy of Sciences, Vol. 1043, 2005, pp. 9-19. doi:10.1196/annals.1333.002
[12] G. Penna, N. Mondaini, S. Amuchastegui, S. D. Innocenti, M. Carini, G. Giubilei, B. Fibbi, E. Colli, M. Maggi and L. Adorini, “Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarker in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia,” European Urology, Vol. 51, No. 2, 2007, pp. 524-533. doi:10.1016/j.e ururo.2006.07.016
[13] K. H. Yoo, S. K. Kim, J. H. Chung and S. G. Chang, “Association of IL10, IL10RA, and IL10RB Polymorphisms with Benign Prostate Hyperplasia in Korean Population,” Journal of Korean Medical Science, Vol. 26, No. 5, 2011, pp. 659-664. doi:10.3346/jkms.2011.26.5.659
[14] T. Kullisaar, S. Türk, M. Punab, P. Korrovits, K. Kisand, A. Rehema, K. Zilmer and M. Zilmer, “Oxidative Stress in Leucocytospermic Prostatitis Patients: Preliminary Results,” Andrologia, Vol. 40, No. 3, 2008, pp. 161-172. doi:10.1111/j.1439-0272.2007.00816.x
[15] A. M. Pontari, “Inflammation and Anti-Inflammatory Therapy in Chronic Prostatitis,” Urology, Vol. 60, No. 6, 2002, pp. 29-33. doi:10.1016/S0090-4295(02)02381-6
[16] G. Robert, M. Salagierski, J. A. Schalken and A. de La Taille, “Inflammation and Benign Prostatic Hyperplasia: Cause or Consequence?” Progrès en Urologie, Vol. 20, No. 6, 2010, pp. 402-407. doi:10.1016/j.purol.2010.03.007
[17] O. F. Karatas, O. Bayrak, E. Cimentepe and D. Unal, “An Insidious Risk Factor for Cardiovascular Disease: Benign Prostatic Hyperplasia,” International Journal of Cardiology, Vol. 144, No. 3, 2010, p. 452. doi:10.1016/j.ijcard.2009.03.099
[18] M. Gacci, L. Vignozzi, A. Sebastianelli, M. Salvi, C. Giannessi, C. De Nunzio, A. Tubaro, G. Corona, G. Rastrelli, R. Santi, G. Nesi, S. Serni, M. Carini and M. Maggi, “Metabolic Syndrome and Lower Urinary Tract Symptoms: The Role of Inflammation,” Prostate Cancer and Prostatic Diseases, Vol. 16, No. 1, 2013, pp. 101-106. doi:10.1038/pcan.2012.44
[19] A. C. Reynolds, J. Dorrian, P. Y. Liu, H. P. Van Dongen, G. A. Wittert, L. J. Harmer and S. Banks, “Impact of Five Nights of Sleep Restriction on Glucose Metabolism, Leptin and Testosterone in Young Adult Men,” PLoS One, Vol. 7, No. 7, 2012, Article ID: e41218. doi:10.1371/journal.pone.0041218
[20] W. G. Witham, K. A. Yester and K. R. McGaffin, “A High Leucine Diet Mitigates Cardiac Injury and Improves Survival after Acute Myocardial Infarction,” Metabolism, Vol. 62, No. 2, 2013, pp. 290-302. doi:10.1016/j.metabol.2012.07.023
[21] S. Vasdev, J. Stuckless and V. Richardson, “Role of the Immune System in Hypertension: Modulation by Dietary Antioxidants,” International Journal of Angiology, Vol. 20, No. 4, 2011, pp. 189-212. doi:10.1055/s-0031-1288941
[22] F. Fusco, R. D. di Villa Bianca, E. Mitidieri, G. Cirino, R. Sorrentino and V. Mirone, “Sildenafil Effect on the Human Bladder Involves the L-Cysteine/Hydrogen Sulfide Pathway: A Novel Mechanism of Action of Phosphodiesterase Type 5 Inhibitors,” European Urology, Vol. 62, No. 6, 2012, pp. 1174-1180. doi:10.1016/j.eururo.2012.07.025
[23] R. Patacchini, P. Santicioli, S. Giuliani and C. A. Maggi, “Hydrogen Sulfide (H2S) Stimulates Capsaicin-Sensitive Primary Afferent Neurons in the Rat Urinary Bladder,” British Journal of Pharmacology, Vol. 142, No. 1, 2004, pp. 31-34. doi:10.1038/sj.bjp.0705764
[24] P. Weinhold, C. Gratzke, T. Streng, C. Stief, K. E. Andersson and P. Hedlund, “TRPA1 Receptor Induced Relaxation of the Human Urethra Involves TRPV1 and Cannabinoid Receptor Mediated Signals, and Cyclooxygenase Activation,” The Journal of Urology, Vol. 183, No. 5, 2010, pp. 2070-2076. doi:10.1016/j.juro.2009.12.093
[25] R. A. Dombkowski, M. M. Doellman, S. K. Head and K. R. Olson, “Hydrogen Sulfide Mediates Hypoxia-Induced Relaxation of Trout Urinary Bladder Smooth Muscle,” Journal of Experimental Biology, Vol. 209, 2006, pp. 3234-3240. doi:10.1242/jeb.02376
[26] C. Gratzke, T. Streng, E. Waldkirch, K. Sigl, C. Stief, K. E. Andersson and P. Hedlund, “Transient Receptor Potential A1 (TRPA1) Activity in the Human Urethra-Evidence for a Functional Role for TRPA1 in the Outflow Region,” European Urology, Vol. 55, No. 3, 2009, pp. 696-704. doi:10.1016/j.eu ruro.2008.04.042
[27] S. Du, I. Araki, H. Kobayashi, H. Zakoji, N. Sawada and M. Takeda, “Differential Expression Profile of Cold (TRPA1) and Cool (TRPM8) Receptors in Human Urogenital Organs,” Urology, Vol. 72, No. 2, 2008, pp. 450-455. doi:10.1016/j.urology.2007.11.127
[28] C. Gratzke, P. Weinhold, O. Reich, M. Seitz, B. Schlenker, C. G. Stief, K. E. Andersson and P. Hedlund, “Transient Receptor Potential A1 and Cannabinoid Receptor Activity in Human Normal and Hyperplastic Prostate: Relation to Nerves and Interstitial Cells,” European Urology, Vol. 57, No. 5, 2010, pp. 902-910. doi:10.1016/j.eururo.2009.08.019
[29] A. Pertovaara and A. Koivisto, “TRPA1 Ion Channel in the Spinal Dorsal Horn as a Therapeutic Target in Central Pain Hypersensitivity and Cutaneous Neurogenic Inflammation,” European Journal of Pharmacology, Vol. 666, No. 1-3, 2011, pp. 1-4. doi:10.1016/j.ejphar.2011.05.027
[30] S. Türk and T. Kullisaar, “Are Prostatitis Symptoms Associated with an Isoprostane-Mediated Vicious Circle?” Medical Hypotheses, Vol. 77, No. 5, 2011, pp. 837-840. doi:10.1016/j.mehy.2011.07.050
[31] M. Pescuma, E. M. Hebert, F. Mozzi and G. F. de Valdes, “Functional Fermented Whey-Based Beverage Using Lactic Acid Bacteria,” International Journal of Food Microbiology, Vol. 141, No. 1-2, 2010, pp. 73-81. doi:10.1016/j.ijfoodmicro.2010.04.011
[32] O. W. Griffith, “Biologic and Pharmacologic Regulation of Mammalian Glutathione Synthesis,” Free Radical Biology and Medicine, Vol. 27, No. 9-10, 1999, pp. 922-935. doi:10.1016/S0891-5849(99)00176-8
[33] M. Zilmer, U. Soomets, A. Rehema and ü. Langel, “The Glutathione System as an Attractice Therapeutic Target,” Letters in Drug Design & Discovery, Vol. 2, 2005, pp. 121-127.
[34] J. M. Hascoet, C. Hubert, F. Rochat, H. Legagneur, S. Gaga, S. Emady-Azar and P. G Steenhout, “Effect of Formula Composition on the Development of Infant Gut Microbiota,” Journal of Pediatric Gastroenterology and Nutrition, Vol. 52, No. 6, 2011, pp. 756-762. doi:10.1097/MPG.0 b013e3182105850
[35] G. Prioult and I. Fliss, “Effect of Probiotic Bacteria and Maintenance of Oral Tolerance to Beta-Lactoglobulin in Gnotobiotic Mice,” Clinical and Diagnostic Laboratory Immunology, Vol. 10, 2003, pp. 787-792.
[36] J. M. Uronis, J. C. Arthur, T. Keku, A. Fodor, I. M. Carroll, M. L. Cruz, C. B. Appleyard and C. Jobin, “Gut Microbial Diversity Is Reduced by the Probiotic VSL#3 and Correlates with Decreased TNBS-Induced Colitis,” Inflammatory Bowel Diseases, Vol. 17, No. 1, 2011, pp. 289-297. doi:10.1002/ibd.21366
[37] N. Larsen, F. K. Vogensen, F. W. van den Berg, D. S. Nielsen, A. S. Andreasen, B. K. Pedersen, W. A. Al-Soud, S. J. Sorensen, L. H. Hansen and M. Jakobsen, “Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults,” PLoS One, Vol. 5, No. 2, 2010, Article ID: e9085. doi:10.1371/journal.pone.0009085
[38] L. Ramchandran and N. P. Shah, “Yogurt Can Beneficially Affect Blood Contributors of Cardiovascular Health Status in Hypertensive Rats,” Journal of Food Science, Vol. 76, No. 4, 2011, pp. 131-136. doi:10.1111/j.1750-3841.2011.02127.x
[39] D. T. Dinh, A. G. Frauman, G. R. Somers, M. Ohishi, J. Zhou, D. J. Casley, C. I. Johnston and M. E. Fabiani, “Evidence for Activation of the Renin-Angiotensin System in the Human Prostate: Increased Angiotensin II and Reduced AT(1) Receptor Expression in Benign Prostatic Hyperplasia,” Journal of Pathology, Vol. 196, No. 2, 2002, pp. 213-219. doi:10.1002/path.1021
[40] A. von Ruesten, S. Feller, M. M. Bergmann and H. Boeing, “Diet and Risk of Chronic Diseases: Results from the First 8 Years of Follow-Up in the EPIC-Potsdam Study,” European Journal of Clinical Nutrition, Vol. 67, No. 4, 2013, pp. 412-419. doi:10.1038/ejcn.2013.7

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.